Insulet Corporation (PODD)
Why Insulet (PODD) Might be Well Poised for a Surge
Insulet (PODD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Insulet Stock Up Post Q3 Earnings & Revenue Beat, Margins Expand
PODD's Q3 earnings and revenues top forecasts, with strong Omnipod growth and margin expansion lifting shares.
New Strong Buy Stocks for Nov. 13: PODD, PRAA, and More
PFBC, WFRD, PODD, PRAA and ALX have been added to the Zacks Rank #1 (Strong Buy) List on Nov. 13, 2025.
PODD Vs. Intuitive Surgical: This Underdog Might Just Win
When it comes to surgical innovation, Intuitive Surgical (NASDAQ: ISRG) often dominates investor attention. But Insulet Corporation (NASDAQ: PODD), best known for its Omnipod insulin delivery system, is emerging as a compelling alternative in the health care equipment space.
Insulet (PODD) Upgraded to Strong Buy: Here's What You Should Know
Insulet (PODD) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
3 Reasons Why Growth Investors Shouldn't Overlook Insulet (PODD)
Insulet (PODD) could produce exceptional returns because of its solid growth attributes.
Insulet (PODD) Q3 Earnings and Revenues Beat Estimates
Insulet (PODD) came out with quarterly earnings of $1.24 per share, beating the Zacks Consensus Estimate of $1.13 per share. This compares to earnings of $0.9 per share a year ago.
Insulet tops quarterly estimates on demand for wearable insulin pumps
Medical device maker Insulet on Thursday posted third-quarter results that surpassed Wall Street's expectations on strong demand for its wearable insulin pumps, which eliminate the need for daily injections.
Ahead of Insulet (PODD) Q3 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Insulet (PODD), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2025.
Insulet (PODD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Insulet (PODD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Insulet Stock Surges 37.4% in 12 months: What's Driving the Rally?
PODD stock rallies 37.4% in a year, fueled by Omnipod 5 adoption, global launches and expanding reach in diabetes care.
Here's Why Insulet (PODD) is a Strong Momentum Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
